Bambusa Therapeutics Completes Enrollment for BBT001 Trial in Atopic Dermatitis
Bambusa Therapeutics has announced the completion of patient enrollment for its Phase 1b/2a trial of BBT001, a bispecific antibody designed to treat moderate-to-severe atopic dermatitis (AD). The trial, conducted in New Zealand and the United States, is a randomized, placebo-controlled study focusing on the safety and tolerability of BBT001. The trial also explores efficacy through various biomarkers. BBT001 targets IL-4Rα and IL-31 signaling pathways, aiming to provide significant relief for patients with AD and other type 2 inflammatory skin diseases. The company plans to release topline results in mid-2026. 
